C

    CytoMed Therapeutics Limited Ordinary Shares (GDTC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.88
    -0.04 (-4.70%)

    Market Cap: $10.89M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(6/10)
    Avg Surprise
    -63.33%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26
    		$0.00N/A+100.00%Beat-
    Sep 25
    		$-0.19$-0.04-375.00%Miss-375.0%
    Jun 25
    		$N/A$0.00N/ABeat-
    Mar 25
    		$-0.12$-0.04-200.00%Miss-200.0%
    Dec 24
    		$N/A$-0.04N/ABeat-
    Sep 24
    		$-0.04$-0.04+0.00%Beat+50.0%
    Jun 24
    		$-0.09$-0.04-125.00%Miss-50.0%
    Mar 24
    		$-0.04$-0.04+0.00%Beat+33.3%
    Dec 23
    		$-0.05$-0.05+0.00%Beat-
    Sep 23
    		$-0.08$-0.06-33.33%Miss-
    Jun 23
    		$-0.06$-0.06+0.00%Beat-
    Mar 23
    		$-0.06$-0.06+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.99EV/EBITDA-4.45x
    Price/FCF-1.63xFCF Yield-61.30%
    Profitability
    Profit Margin0.00%Operating Margin-535.00%
    ROE-50.30%ROIC-83.03%
    Financial Health
    Debt/Equity0.06xInterest Coverage-184.87x
    Current Ratio5.17xQuick Ratio3.66x
    Trading Statistics
    Beta0.05Avg Volume26.38K
    52-Week High$3.6852-Week Low$0.68

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.94
    SMA 20$0.90
    SMA 50$0.95
    SMA 200$1.13
    EMA 10$0.93
    EMA 20$0.92
    EMA 50$0.95
    EMA 200$1.20

    MACD

    Line: 0.00Signal: -0.00Hist: 0.00

    ADX

    ADX: 19.9+DI: 17.5-DI: 22.3

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down4.0
    PSAR$1.06

    Bollinger Bands

    Upper Band$1.03
    Lower Band$0.76
    %B Position3086%(Upper)
    Band Width0.43

    RSI (14-Day)

    Neutral
    45.6

    Momentum Oscillators

    Stoch %K55.9
    Stoch %D66.3
    Williams %R-57.1
    ROC (10d)-3.2%
    Momentum-0.03
    CCI (20d)-43.2
    MFI (14d)70.0

    Volatility Measures

    ATR (14d)$0.10(11.5%)
    StdDev (20d)0.07
    Hist Vol97.5%(High)

    Volume Flow

    VWAP$0.86
    OBV15.5M
    AD Line9.0M
    CMF (20d)-0.108

    Volume Metrics

    Avg Vol (20d)27.4K
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.89

    Pivot Points

    R3$1.00
    R2$0.96
    R1$0.94
    Pivot Point$0.90
    S1$0.88
    S2$0.84
    S3$0.82

    Advanced Oscillators

    TSI0.00
    Ultimate Osc66.4
    KST1.85

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$167,945$205,081$134,896$134,721$141,701$112,038$112,385N/A$111,956$142,249$141,851N/A
    Cost of Revenue$723,598$31,988$9,349N/A$14,637$1,103$1,106$38,231$1,187$205,722$3,043$39,094
    Gross Profit$-555,651$173,092$125,547$125,385$127,065$110,935$111,278$-38,231$110,769$-63,472$138,806$-39,094
    Operating Expenses$1.80M$834,204$777,092$776,087$646,066$641,162$643,153$1.48M$548,379$492,507$491,128$987,285
    R&D$1.05M$527,514$583,345$582,591$474,620$858,882$488,482$576,611$389,888$406,053$404,916$659,711
    SG&A$0$285,314$0$161,289$163,761$149,874$150,340$0$154,012$684,758$74,048$0
    Operating Income$-2,356,388$-661,112$-651,544$-650,703$-519,000$-530,227$-531,872$-1,516,560$-437,608$-1,575,424$-1,012,924$-1,026,380
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$10,560$5,092$9,938$5,165$208,481$9,863$10,316$0$551,308$41,285$61,000$45,334
    Income Before Tax$-1,744,762$-875,254$-1,126,993$-1,125,537$-727,481$-544,014$-545,704$-1,454,043$-988,916$-2,186,247$-1,077,147$-1,524,587
    Income Tax Expense$0$0$0$0$0$569,042$0$0$0$14,676$0$0
    Net Income$-1,730,996$-868,349$-1,125,955$-1,124,500$-724,934$-1,095,028$-545,630$-1,462,903$-989,175$-1,080,104$-1,077,077$-1,533,752
    EBITDA$-2,224,675$-995,612$-1,026,444$-1,025,118$-668,826N/A$-743,482$-1,478,330$-820,181N/A$-911,565$-987,290
    EBIT$-2,356,388$-1,097,696$-1,116,500$-1,115,057$-751,476N/A$-827,136$-1,516,561$-908,275N/A$-1,012,923$-1,026,384
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GDTC

    News

    CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), indicating a "Strong Buy" rating with a target price of $5.00, representing a 143.90% upside. The forecast is based on zero analysts, and key financial data like EPS, Revenue, EBIT, and Net Profit are not yet disclosed by the company.

    TradingKey•8/13/26•
    Bullish

    CytoMed Therapeutics Ltd SEC Filing (Aug 11, 2026)

    This article reports on CytoMed Therapeutics Ltd's (GDTC) SEC Form 144 filing from August 11, 2026. The filing indicates a proposed sale of securities under Rule 144, detailing information about the issuer, securities to be sold (Ordinary Shares acquired on 04/22/2021), and the transaction details. It also includes general company information, recent news, and other SEC filings.

    Stock Titan•8/11/26•
    Neutral

    GDTC|CytoMed Therapeutics Ltd|Price:0.960|Chg%:+0.030

    This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its current stock price, market cap, key financial figures, and recent performance. It highlights the company's focus on developing cell-based immunotherapies for cancer, specifically utilizing gamma delta T cell and natural killer T cell technologies. The report also includes analyst ratings, peer comparisons, and a breakdown of major shareholders.

    TradingKey•8/4/26•
    Somewhat-Bearish

    CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), detailing its current support, resistance levels, and the readings from various technical indicators and moving averages. According to the analysis, the overall signal is Neutral based on moving averages and other technical indicators, with specific breakdowns of buy and sell signals for different indicators.

    TradingKey•7/29/26•
    Neutral

    CytoMed Therapeutics Ltd (GDTC) Institutional Confidence

    This article provides an overview of institutional holdings in CytoMed Therapeutics Ltd (GDTC), indicating shareholder activity and changes in shares held by various entities. Key shareholders include Glorious Finance Limited, mDR Limited, and 28 Consultants Ltd, with some showing recent changes in their positions. The company traded at $0.880, down 11.11%, with a market capitalization of $10.41 million.

    TradingKey•7/27/26•
    Bearish

    Frequently Asked Questions About GDTC

    Does GDTC pay dividends?
    CytoMed Therapeutics Limited Ordinary Shares (GDTC) does not currently pay a regular dividend.
    What is GDTC's market cap?
    CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a market capitalization of $10.89M with a current stock price of $0.88.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In